Spyre Therapeutics (SYRE) Operating Income: 2015-2025
Historic Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$56.9 million.
- Spyre Therapeutics' Operating Income fell 2.70% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$208.6 million for FY2024, which is 13.92% up from last year.
- Per Spyre Therapeutics' latest filing, its Operating Income stood at -$56.9 million for Q3 2025, which was down 35.66% from -$41.9 million recorded in Q2 2025.
- Spyre Therapeutics' 5-year Operating Income high stood at -$6.7 million for Q2 2021, and its period low was -$159.2 million during Q2 2023.
- Over the past 3 years, Spyre Therapeutics' median Operating Income value was -$47.8 million (recorded in 2024), while the average stood at -$54.8 million.
- In the last 5 years, Spyre Therapeutics' Operating Income crashed by 610.19% in 2023 and then surged by 72.28% in 2024.
- Spyre Therapeutics' Operating Income (Quarterly) stood at -$20.4 million in 2021, then climbed by 6.26% to -$19.2 million in 2022, then slumped by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then dropped by 2.70% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$41.9 million for Q2 2025, and -$53.6 million during Q1 2025.